PL-3994 for Difficult-to-Control Hypertension Indications

PL-3994, a natriuretic peptide receptor A (“NPRA”) agonist compound, is being developed for treatment of hypertension associated with kidney dialysis, resistant hypertension and other difficult-to-control hypertension indications.  While there are a large number of approved drugs for treatment of hypertension, there are no approved drugs for hypertension that are active through the NPRA system.

Over 300,000 Americans are on dialysis.  Hypertension, particularly interdialytic hypertension, is a common finding in dialysis patients. Based upon multiple studies, over 50 to 60 percent of hemodialysis patients (up to 85 percent in some reports) and nearly 30 percent of peritoneal dialysis patients are hypertensive.

PL-3994 is a synthetic molecule, incorporating a novel and proprietary amino acid mimetic developed by Palatin Technologies.  PL-3994 has an extended half-life, with reduced affinity for natriuretic peptide clearance receptors and increased resistance to neutral endopeptidase, an endogenous enzyme that degrades natriuretic peptides. The result is a drug with improved pharmacokinetic and pharmacodynamic properties.

For more information on PL-3994 for Difficult-to-Control Hypertension Indications, download the fact sheet.